Try a new search

Format these results:

Searched for:



Total Results:


Increasing Influenza Vaccination Rate with Institution-wide Mandatory Program and Allergy Evaluation [Meeting Abstract]

Nassau, S M; Banta, E M; Rosner, G A; Aquino, M R; Hetzer, G; Salvati, S; Cohan, C; Fonacier, L S
Rationale: Mandatory influenza vaccination for all hospital employees is increasingly common, and was a policy at NYU Langone Health System (NYC, Winthrop, Lutheran) in 2017. Employees applying for exemption based on prior allergic reaction underwent evaluation by an allergist. We assessed the success of mandating the vaccine and whether allergic evaluation increased vaccination rates. Method(s): Prior reaction history, skin testing, and outcomes of evaluation were reviewed from charts. Primary outcomes were total vaccination rate and outcomes of those that applied for exemption. Result(s): A total of 39,146 of 39,558 employees (98.9%) received vaccination without evaluation. Of 39,558 employees, 419 (0.01%) applied for exemption; 73 sought exemption based on prior allergic reaction. Exemption was granted to 303 employees for other reasons. Egg-free vaccine was administered to 38/73 (52%) who reported egg allergy. The remaining 35 underwent allergy evaluation; 15 were granted exemption while 20 (57%) were vaccinated. At Winthrop, 46 employees applied for medical exemption due to allergy; 45 (97%) were ultimately vaccinated. Eight employees with reported vaccine allergy were evaluated. Four received the vaccine without testing, while four were skin tested. One patient developed a generalized rash with skin testing and was granted exemption. The other three successfully received influenza vaccine via graded challenge. Institution-wide, 99.04% (39,182 of 39,558) of employees received the vaccine. Conclusion(s): Mandating flu vaccination is by itself an effective method to ensure compliance (98.9%). Allergy evaluation increased the vaccination rate in those applying for an exemption due to allergy, with only 15/73 (20%) granted exemption.
ISSN: 1097-6825
CID: 3637902

Differential expression of microRNAs in exhaled breath condensates of patients with asthma, patients with chronic obstructive pulmonary disease, and healthy adults [Letter]

Pinkerton, Mark; Chinchilli, Vernon; Banta, Erin; Craig, Timothy; August, Avery; Bascom, Rebecca; Cantorna, Margherita; Harvill, Eric; Ishmael, Faoud T
PMID: 23628339
ISSN: 1097-6825
CID: 3427902

A challenging diagnosis of alpha-1-antitrypsin deficiency: identification of a patient with a novel F/Null phenotype

Ringenbach, Michael R; Banta, Erin; Snyder, Melissa R; Craig, Timothy J; Ishmael, Faoud T
Alpha-1-antitrypsin (A1AT) deficiency is a genetic disease characterized by low levels and/or function of A1AT protein. A1AT deficiency can result in the development of COPD, liver disease, and certain skin conditions. The disease can be diagnosed by demonstrating a low level of A1AT protein and genotype screening for S and Z mutations, which are the most common. However, there are many genetic variants in A1AT deficiency, and this screening may miss rarer cases, such as those caused by dysfunctional protein. We identified a patient with a previously unreported F/null phenotype that was missed by routine screening. This case highlights the wide variation in possible mutations, limitations in diagnostics, and the importance of combining clinical suspicion with measurement of protein levels, phenotypic analysis, and in appropriate cases expanded genetic analysis.
PMID: 22078084
ISSN: 1710-1492
CID: 3427892

Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials

Banta, Erin; Horn, Patrick; Craig, Timothy J
Hereditary Angioedema (HAE) is a rare, debilitating, genetic disorder characterized by acute attacks of edema without urticaria. Ecallantide, a direct plasma kallikrein inhibitor, is approved for treatment of acute HAE attacks. This article addresses the efficacy of ecallantide in the treatment of moderate-to-severe attacks of HAE based on time to treatment. A post hoc integrated analysis of the EDEMA4 and EDEMA3-DB clinical trials was performed based on the time to patient's treatment, defined as the time from initial recognition of moderate-to-severe symptoms to dosing (cohort, 0-2, >2-4, >4-6, >6-8, and >8 hours). Mean symptom complex severity (MSCS) score and treatment outcome score (TOS) were analyzed. Complete or near-complete resolution of symptoms was assessed at 4 and 24 hours. In this analysis, 70 patients received 30 mg of subcutaneous (s.c.) ecallantide and 73 patients received placebo. Change from baseline in MSCS score and TOS at 4 hours revealed significantly better response to ecallantide versus placebo for patients treated >2-4 (n = 46; p = 0.002; p = 0.003) or >4-6 (n = 47; p = 0.044; p = 0.043) hours after symptom onset. Fewer patients were treated within 2 hours of symptom onset; for these patients (n = 10; p = 0.752; p = 0.422) treatment did not achieve statistical significance. For overall response, complete or near-complete resolution was greatest within the 0- to 2-hour cohort (71.4%). As with other therapies for HAE early ecallantide therapy is optimal. Treatment with ecallantide within 6 hours of symptom onset leads to more rapid and sustained improvement of symptoms.
PMID: 21781409
ISSN: 1539-6304
CID: 3427872

A 64-year-old man with chronic obstructive pulmonary disease and an atypical rash [Case Report]

Craig, Ethan T; Banta, Erin; Craig, Timothy J
A 64-year-old male patient with a 15-year history of chronic obstructive pulmonary disease presented with an atypical rash that was refractory to standard therapy. Pulmonary function tests confirmed an obstructive lung disease. Basic laboratory workup revealed conflicting information, leading to a diagnostic challenge discussed in this article. Ultimately, careful testing did reveal the diagnosis and the patient was treated accordingly.
PMID: 21781410
ISSN: 1539-6304
CID: 3427882

Ecallantide for the treatment of hereditary angiodema in adults

Lunn, Michael; Banta, Erin
Hereditary angioedema (HAE) is a clinical disorder characterized by a deficiency of C1 esterase inhibitor (C1-INH). HAE has traditionally been divided into two subtypes. Unique among the inherited deficiencies of the complement system, HAE Types I and II are inherited as an autosomal dominant disorder. The generation of an HAE attack is caused by the depletion and/or consumption of C1-inhibitor manifested as subcutaneous or submucosal edema of the upper airway, face, extremities, or gastrointestinal tract mediated by bradykinin. Attacks can be severe and potentially life-threatening, particularly with laryngeal involvement and treatment of acute attacks in the United States has been severely limited. In December 2009 the FDA approved ecallantide for the treatment of acute HAE attacks. Ecallantide is a small recombinant protein acting as a potent, specific and reversible inhibitor of plasma kallikrein which binds to plasma kallikrein blocking its binding site, directly inhibiting the conversion of high molecular weight kininogen to bradykinin. Administered subcutaneously, ecallantide was demonstrated in two clinical trials, EDEMA3 and EDEMA4, to decrease the length and severity of acute HAE attacks. Although there is a small risk for anaphylaxis, which limits home administration, ecallantide is a novel, safe, effective and alternative treatment for acute HAE attacks.
PMID: 21695090
ISSN: 1179-5468
CID: 3427922

Recruitment of mammalian cell fibronectin to the surface of Chlamydia trachomatis

Kleba, Betsy J; Banta, Erin; Lindquist, Erika A; Stephens, Richard S
Pathogenic bacteria exploit the presence of various host cell molecules in order to colonize new tissues. Fibronectin is involved in a wide range of cell functions in vivo, and staphylococci, streptococci, and gonococci have evolved mechanisms to utilize this glycoprotein to mediate host cell binding. We show that elementary bodies (EB) from two biovars of Chlamydia trachomatis recruit fibronectin to their surfaces upon lysis of the host cell. We also demonstrate that a heparan sulfate lyase-sensitive molecule on chlamydial EB is responsible for binding at least a portion of this fibronectin.
PMID: 12065538
ISSN: 0019-9567
CID: 3427912